Want to see ES:ORY full AI Analyst Report?
ORY Stock Chart & Stats
€3.22
€0.02(1.34%)
At close: 4:00 PM EST
€3.22
€0.02(1.34%)
Day’s Range― - ―
52-Week Range€2.56 - €4.02
Previous CloseN/A
Volume6.85K
Average Volume (3M)1.68M
Market Cap
€243.81M
Enterprise Value€234.01M
Total Cash (Recent Filing)€31.11M
Total Debt (Recent Filing)€13.73M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Jul 29, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding79,887,700
10 Day Avg. Volume2,474,153
30 Day Avg. Volume1,678,358
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.48Price Target Upside101.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.12
Revenue Forecast (FY)€8.20M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Supportive Balance SheetOryzon's low debt-to-equity and meaningful equity base provide financing flexibility for multi-year clinical development, reducing near-term refinancing risk and preserving optionality for partnerships or licensing deals that require runway to reach value-driving catalysts.
Focused Epigenetics PipelineA clear strategic focus on epigenetic targets (LSD1/KDM1A inhibitors) concentrates scientific expertise and assets, improving chances to progress candidates and attract partner interest in niche, high-barrier-to-entry therapeutic areas versus broadly diversified R&D programs.
Partnership & Licensing Revenue ModelA business model that emphasizes collaborations and licensing can monetize clinical milestones and de-risk commercialization, enabling the company to access partner funding, share late-stage costs, and convert R&D progress into non-dilutive or milestone-driven cash inflows over time.
Bears Say
Persistent Operating LossesSustained operating and net losses indicate the company remains pre-commercial and reliant on external financing; prolonged unprofitability can dilute shareholders, constrain strategic choices, and necessitate recurring capital raises that distract management from long-term value creation.
Weak Cash GenerationConsistently negative operating and free cash flow show development costs outstrip cash receipts, creating dependency on financing or partnerships. Even with modest improvement, this structural cash burn limits self-funding capacity and heightens financing and execution risk over the next several quarters.
Irregular / Zero Revenue YearsHighly inconsistent revenue, including multiple zero-revenue years, undermines predictability of cash inflows and makes forecasting partnership receipts or milestone timing difficult, which complicates strategic planning and increases the chance of unplanned financing or delayed programs.
Oryzon Genomics SA News
ORY FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
Oryzon Genomics SA lowest stock price was €2.56 and its highest was €4.02 in the past 12 months.
What is Oryzon Genomics SA’s market cap?
Oryzon Genomics SA’s market cap is €243.81M.
When is Oryzon Genomics SA’s upcoming earnings report date?
Oryzon Genomics SA’s upcoming earnings report date is Jul 29, 2026 which is in 27 days.
How were Oryzon Genomics SA’s earnings last quarter?
Oryzon Genomics SA released its earnings results on May 14, 2026. The company reported -€0.017 earnings per share for the quarter, the consensus estimate of -€0.017 by €0.
Is Oryzon Genomics SA overvalued?
According to Wall Street analysts Oryzon Genomics SA’s price is currently Undervalued.
Does Oryzon Genomics SA pay dividends?
Oryzon Genomics SA does not currently pay dividends.
What is Oryzon Genomics SA’s EPS estimate?
Oryzon Genomics SA’s EPS estimate is -0.06.
How many shares outstanding does Oryzon Genomics SA have?
Oryzon Genomics SA has 79,887,700 shares outstanding.
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Oryzon Genomics SA reported an EPS of -€0.017 in its last earnings report, expectations of -€0.017. Following the earnings report the stock price went up 2.253%.
Which hedge fund is a major shareholder of Oryzon Genomics SA?
Currently, no hedge funds are holding shares in ES:ORY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
ORY Stock 12 Month Forecast
Average Price Target
€6.48
▲(101.37% Upside)
Technical Analysis
Options Prices
Currently, No data available
---